WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Nicola Peltz cements the end of 'feud' with 'beautiful' motherAmanda Holden reveals a huge secret about THAT nude appearance on her Heart FM breakfast showItaly earns 5th Champions League spot for next season because of overall success in EuropeArizona State hit with NCAA sanctions for improper football recruiting visits during pandemicThe 20 best shows to watch On Demand this weekendThe US attempts a new military deal with Niger in a last ditch effort to stayPregnant Rooney Mara dresses her baby bump in headPregnant Rooney Mara dresses her baby bump in head5,000 flee military raids on villages in Myanmar’s Sagaing region — Radio Free AsiaTodd, Julie Chrisley appeal bank fraud and tax evasion convictions
3.1677s , 6499.6953125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Wanderer news portal